Abstract 714
Background
Prognosis of GBM is especially poor for unresected patients even when treated with the standard EORTC regimen.
Methods
We analyzed clinical characteristics, median progression free survival (PFS) and median overall survival (OS) of unresected patients from the database of the GLIOCAT study (432 patients uniformly treated with the EORTC regimen).
Results
Sixty-five patients began concurrent therapy. OS for all patients who started treatment was 7.2 months (95% CI:4.3-10.2). Fourteen patients could not even complete the concomitant phase (TMZ + RxT) (21.5%). Fifty-one patients (78.5%) completed concomitant treatment and are described here. Median age: 61 years old (29 males and 22 females). Multifocal tumor in 12 patients. Median lapsed time to start RT: 4 weeks. PFS was 6 months (95% CI: 3.9-8.03) and OS was 9 months (95% CI:6.4-11.5). MGMT status was available for 31 patients. OS and PFS were 12 months (95% CI: 5.1-18.7) and 8 months (95% CI: 6.5-9.4) for mMGMT vs 7 months (95% CI: 1.1-12.8) and 5 months (95% CI: 3.2-6.7) for mMGMT (NS). Only age (older than ≥50) emerged as a poor prognostic factor: OS 8 (95% CI: 5.7-10.2) vs. 19 (95% CI: 9.4-28.5); P = 0.05. Treatment at recurrence was administered to 20 patients (30.7%). OS and PFS for those patients was 18 months (95% CI: 15.3-20.6) and 7 months (95% CI: 5.9-8.0), respectively, compared with 6 months (95% CI: 5.0-6.9) and 4 months (95% CI: 1.6-6.3) for patients without a second line treatment.
Conclusions
Median OS for unresected patients treated with the standard treatment is similar to that reported in the pivotal trial. However, 21.5% could not even complete concurrent therapy, and only 30.7% could receive a second line therapy.
Clinical trial identification
Legal entity responsible for the study
GLIOCAT
Funding
GLIOCAT
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
ZUMA-3: A phase 1/2 multi-center study evaluation the safety and efficacy of KTE-C19 anti-CD19 CAR T cells in adult patients with relapsed/refractory B precursor acute lymphoblastic leukemia (R/R ALL)
Presenter: Bijal Shah
Session: Poster display
Resources:
Abstract
ZUMA-2: A phase 2 multi-center study evaluating the efficacy of KTE-C19 (Anti-CD19 CAR T cells) in patients with relapsed/refractory Mantle cell lymphoma (R/R MCL)
Presenter: Michael Wang
Session: Poster Display
Resources:
Abstract
ZUMA-1: A phase 2 multi-center study evaluating anti-CD19 chimeric antigen receptor (CAR) T cells in patients with refractory aggressive non-Hodgkin lymphoma (NHL)
Presenter: Sattva Neelapu
Session: Poster Display
Resources:
Abstract
Younger age as a prognostic indicator in breast cancer: Correlation between clinical-pathologic factors and miRNAs and long-term follow-up
Presenter: Maria Teresa Martinez
Session: Poster display
Resources:
Abstract
Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO)
Presenter: Christy Toms
Session: Poster display
Resources:
Abstract
Whole exome sequencing (WES) and RNA sequencing (RNA-seq) in routine clinical practice for colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) patients (pts)
Presenter: Géraldine Perkins
Session: Poster display
Resources:
Abstract
What is the optimal annual interpretive volume for a radiologist reading screening mammograms?
Presenter: Asli Uluturk
Session: Poster display
Resources:
Abstract
What decides breast conservation versus mastectomy in the background of diverse sociocultural environment, an Indian study
Presenter: Poonamalle Padmanabhan Bapsy
Session: Poster display
Resources:
Abstract
Waiting time to diagnosis and treatment of the head and neck cancer in four institutions in Portugal
Presenter: Ana Castro
Session: Poster display
Resources:
Abstract
Wait times for diagnosis and treatment of lung cancer: a single centre experience
Presenter: Catherine Labbe
Session: Poster Display
Resources:
Abstract